Arterial and venous thrombosis in endocrine diseases

Seminars in Thrombosis and Hemostasis

Volumn 39, Issue 5, 2013, Pages 489-495

  Van Zaane, Bregje ^a,b   Stuijver, Dankaj F ^a,b   Squizzato, Alessandro ^c   Gerdes, Victore A ^a,b  

^a Department of Internal Medicine ^*  (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

aldosterone; cortisol; growth hormone; hyperprolactinemia; parathyroid hormone; pheochromocytoma; thrombosis; thyroid hormone

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CATECHOLAMINE; CINACALCET; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRINOGEN; GLUCOCORTICOID; GROWTH HORMONE; HYDROCORTISONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROLACTIN; SOMATOMEDIN C; SPIRONOLACTONE; VON WILLEBRAND FACTOR;

ACROMEGALY; ADDISON DISEASE; ARTERY THROMBOSIS; ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); CORTICOSTEROID BLOOD LEVEL; CUSHING SYNDROME; DISEASE ASSOCIATION; DRUG SAFETY; ENDOCRINE DISEASE; EVIDENCE BASED MEDICINE; FIBRINOGEN BLOOD LEVEL; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; HEART ATRIUM FIBRILLATION; HEMOSTASIS; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERALDOSTERONISM; HYPERCORTISOLISM; HYPERPARATHYROIDISM; HYPERPROLACTINEMIA; HYPERTENSION; HYPERTHYROIDISM; HYPOTHYROIDISM; INCIDENCE; ISCHEMIC HEART DISEASE; META ANALYSIS; MORTALITY; PARAGANGLIOMA; PARTIAL THROMBOPLASTIN TIME; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; RISK FACTOR; SYSTEMATIC REVIEW; THYROID DISEASE; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; VON WILLEBRAND DISEASE;

ARTERIAL OCCLUSIVE DISEASES; ENDOCRINE SYSTEM DISEASES; GROWTH HORMONE; HEMOSTASIS; HUMANS; HYDROCORTISONE; THROMBOSIS; THYROID DISEASES; VENOUS THROMBOSIS;

EID: 84879118747     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0033-1343889     Document Type: Article

References (76)

1. Flynn R. W., Macdonald T. M., Jung R. T., Morris A. D., Leese G. P. Mortality and vascular outcomes in patients treated for thyroid dysfunction. J Clin Endocrinol Metab: 2006; 91 6 2159 2164
2. Osman F., Franklyn J. A., Holder R. L., Sheppard M. C., Gammage M. D. Cardiovascular manifestations of hyperthyroidism before and after antithyroid therapy: a matched case-control study. J Am Coll Cardiol: 2007; 49 1 71 81
3. van Zaane B., Reuwer A. Q., Büller H. R., Kastelein J. J., Gerdes V. E., Twickler M. T. Hormones and cardiovascular disease: a shift in paradigm with clinical consequences? Semin Thromb Hemost: 2009; 35 5 478 487
4. Völzke H., Schwahn C., Wallaschofski H., Dörr M. Review: The association of thyroid dysfunction with all-cause and circulatory mortality: is there a causal relationship? J Clin Endocrinol Metab: 2007; 92 7 2421 2429
5. Stuijver D. J., van Zaane B., Romualdi E., Brandjes D. P., Gerdes V. E., Squizzato A. The effect of hyperthyroidism on procoagulant, anticoagulant and fibrinolytic factors: a systematic review and meta-analysis. Thromb Haemost: 2012; 108 6 1077 1088
6. Baumgartner-Parzer S. M., Wagner L., Reining G., et al. Increase by tri-iodothyronine of endothelin-1, fibronectin and von Willebrand factor in cultured endothelial cells. J Endocrinol: 1997; 154 2 231 239
7. Shih C. H., Chen S. L., Yen C. C., et al. Thyroid hormone receptor-dependent transcriptional regulation of fibrinogen and coagulation proteins. Endocrinology: 2004; 145 6 2804 2814
8. Hooper J. M., Stuijver D. J., Orme S. M., et al. Thyroid dysfunction and fibrin network structure: a mechanism for increased thrombotic risk in hyperthyroid individuals. J Clin Endocrinol Metab: 2012; 97 5 1463 1473
9. Collet T. H., Gussekloo J., Bauer D. C., et al. Thyroid Studies Collaboration Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med: 2012; 172 10 799 809
10. Lin H. C., Yang L. Y., Kang J. H. Increased risk of pulmonary embolism among patients with hyperthyroidism: a 5-year follow-up study. J Thromb Haemost: 2010; 8 10 2176 2181
11. Kootte R. S., Stuijver D. JF, Dekkers O. M., et al. The incidence of venous thromboembolism in patients with overt hyperthyroidism: a retrospective multicentre cohort study. Thromb Haemost: 2012; 107 3 417 422
12. van Zaane B., Squizzato A., Huijgen R., et al. Increasing levels of free thyroxine as a risk factor for a first venous thrombosis: a case-control study. Blood: 2010; 115 22 4344 4349
13. Debeij J., Dekkers O. M., Asvold B. O., et al. Increased levels of free thyroxine and risk of venous thrombosis in a large population-based prospective study. J Thromb Haemost: 2012; 10 8 1539 1546
14. Manfredi E., van Zaane B., Gerdes V. E., Brandjes D. P., Squizzato A. Hypothyroidism and acquired von Willebrand's syndrome: a systematic review. Haemophilia: 2008; 14 3 423 433
15. Stuijver D. JF. The Hormonal Influence on the Haemostatic System and the Risk of Thrombosis [thesis]. University of Amsterdam: 2012;. ISBN 978-94-6191-460-6
16. Squizzato A., Romualdi E., Büller H. R., Gerdes V. E. Clinical review: Thyroid dysfunction and effects on coagulation and fibrinolysis: a systematic review. J Clin Endocrinol Metab: 2007; 92 7 2415 2420
17. Klein I., Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med: 2001; 344 7 501 509
18. Duntas L. H., Brenta G. The effect of thyroid disorders on lipid levels and metabolism. Med Clin North Am: 2012; 96 2 269 281
19. Ochs N., Auer R., Bauer D. C., et al. Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med: 2008; 148 11 832 845
20. Ladenson P. W., Kristensen J. D., Ridgway E. C., et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med: 2010; 362 10 906 916
21. Moreno M., de Lange P., Lombardi A., Silvestri E., Lanni A., Goglia F. Metabolic effects of thyroid hormone derivatives. Thyroid: 2008; 18 2 239 253
22. Bolland M. J., Holdaway I. M., Berkeley J. E., et al. Mortality and morbidity in Cushing's syndrome in New Zealand. Clin Endocrinol (Oxf): 2011; 75 4 436 442
23. Clayton R. N. Mortality in Cushing's disease. Neuroendocrinology: 2010; 92 01 71 76
24. Baykan M., Erem C., Gedikli O., et al. Impairment of flow-mediated vasodilatation of brachial artery in patients with Cushing's syndrome. Endocrine: 2007; 31 3 300 304
25. Faggiano A., Pivonello R., Spiezia S., et al. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab: 2003; 88 6 2527 2533
26. Van Zaane B., Nur E., Squizzato A., et al. Hypercoagulable state in Cushing's syndrome: a systematic review. J Clin Endocrinol Metab: 2009; 94 8 2743 2750
27. Kastelan D., Dusek T., Kraljevic I., et al. Hypercoagulability in Cushing's syndrome: the role of specific haemostatic and fibrinolytic markers. Endocrine: 2009; 36 1 70 74
28. Manetti L., Bogazzi F., Giovannetti C., et al. Changes in coagulation indexes and occurrence of venous thromboembolism in patients with Cushing's syndrome: results from a prospective study before and after surgery. Eur J Endocrinol: 2010; 163 5 783 791
29. van der Pas R., de Bruin C., Leebeek F. W., et al. The hypercoagulable state in Cushing's disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy. J Clin Endocrinol Metab: 2012; 97 4 1303 1310
30. Boscaro M., Sonino N., Scarda A., et al. Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome. J Clin Endocrinol Metab: 2002; 87 8 3662 3666
31. Koutroumpi S., Daidone V., Sartori M. T., et al. Venous thromboembolism in patients with Cushing's syndrome: need of a careful investigation of the prothrombotic risk profile. Pituitary: 2012; (e-pub ahead of print)
32. Stuijver D. J., van Zaane B., Feelders R. A., et al. Incidence of venous thromboembolism in patients with Cushing's syndrome: a multicenter cohort study. J Clin Endocrinol Metab: 2011; 96 11 3525 3532
33. Wei L., MacDonald T. M., Walker B. R. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med: 2004; 141 10 764 770
34. Fardet L., Petersen I., Nazareth I. Risk of cardiovascular events in people prescribed glucocorticoids with iatrogenic Cushing's syndrome: cohort study. BMJ: 2012; 345 e4928
35. Calvo-Alén J., Toloza S. M., Fernández M., et al. LUMINA Study Group Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients. Arthritis Rheum: 2005; 52 7 2060 2068
36. Stolz E., Klötzsch C., Schlachetzki F., Rahimi A. High-dose corticosteroid treatment is associated with an increased risk of developing cerebral venous thrombosis. Eur Neurol: 2003; 49 4 247 248
37. Stuijver D. J., Majoor C. J., van Zaane B., et al. Use of oral glucocorticoids and the risk of pulmonary embolism: a population-based case-control study. Chest: 2012; (e-pub ahead of print)
38. Bergthorsdottir R., Leonsson-Zachrisson M., Odén A., Johannsson G. Premature mortality in patients with Addison's disease: a population-based study. J Clin Endocrinol Metab: 2006; 91 12 4849 4853
39. Hochberg Z., Pacak K., Chrousos G. P. Endocrine withdrawal syndromes. Endocr Rev: 2003; 24 4 523 538
40. van den Akker E. L., Koper J. W., van Rossum E. F., et al. Glucocorticoid receptor gene and risk of cardiovascular disease. Arch Intern Med: 2008; 168 1 33 39
41. Presotto F., Fornasini F., Betterle C., Federspil G., Rossato M. Acute adrenal failure as the heralding symptom of primary antiphospholipid syndrome: report of a case and review of the literature. Eur J Endocrinol: 2005; 153 4 507 514
42. Cervera R., Piette J. C., Font J., et al. Euro-Phospholipid Project Group Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum: 2002; 46 4 1019 1027
43. Schürmeyer T. H., Engeroff B., Dralle H., von zur Mühlen A. Cardiological effects of catecholamine-secreting tumours. Eur J Clin Invest: 1997; 27 3 189 195
44. Higashi Y., Sasaki S., Nakagawa K., et al. Excess norepinephrine impairs both endothelium-dependent and -independent vasodilation in patients with pheochromocytoma. Hypertension: 2002; 39 2, Pt 2 513 518
45. Holaj R., Zelinka T., Wichterle D., et al. Increased carotid intima-media thickness in patients with pheochromocytoma in comparison to essential hypertension. J Hum Hypertens: 2009; 23 5 350 358
46. von Känel R., Dimsdale J. E. Effects of sympathetic activation by adrenergic infusions on hemostasis in vivo. Eur J Haematol: 2000; 65 6 357 369
47. de Peuter O. R., Souverein P. C., Klungel O. H., Büller H. R., de Boer A., Kamphuisen P. W. Non-selective vs. selective beta-blocker treatment and the risk of thrombo-embolic events in patients with heart failure. Eur J Heart Fail: 2011; 13 2 220 226
48. Hoppener M. R., Kraaijenhagen R. A., Hutten B. A., Büller H. R., Peters R. J., Levi M. Beta-receptor blockade decreases elevated plasma levels of factor VIII:C in patients with deep vein thrombosis. J Thromb Haemost: 2004; 2 8 1316 1320
49. Farahnak P., Lärfars G., Sten-Linder M., Nilsson I. L. Mild primary hyperparathyroidism: vitamin D deficiency and cardiovascular risk markers. J Clin Endocrinol Metab: 2011; 96 7 2112 2118
50. Hagström E., Hellman P., Larsson T. E., et al. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation: 2009; 119 21 2765 2771
51. Vestergaard P., Mollerup C. L., Frokjaer V. G., Christiansen P., Blichert-Toft M., Mosekilde L. Cardiovascular events before and after surgery for primary hyperparathyroidism. World J Surg: 2003; 27 2 216 222
52. Floege J., Kim J., Ireland E., et al. ARO Investigators Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant: 2011; 26 6 1948 1955
53. Chertow G. M., Block G. A., Correa-Rotter R., et al. EVOLVE Trial Investigators Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med: 2012; 367 26 2482 2494
54. Chertok-Shacham E., Ishay A., Lavi I., Luboshitzky R. Biomarkers of hypercoagulability and inflammation in primary hyperparathyroidism. Med Sci Monit: 2008; 14 12 CR628 CR632
55. Erem C., Kocak M., Hacihasanoglu A., Yilmaz M., Saglam F., Ersoz H. O. Blood coagulation, fibrinolysis and lipid profile in patients with primary hyperparathyroidism: increased plasma factor VII and X activities and D-Dimer levels. Exp Clin Endocrinol Diabetes: 2008; 116 10 619 624
56. Erem C., Kocak M., Nuhoglu I., Yilmaz M., Ucuncu O. Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism. Eur J Endocrinol: 2009; 160 5 863 868
57. Viganò G., Gotti E., Comberti E., Giangrande A., Trevisan R., Remuzzi G. Hyperparathyroidism does not influence the abnormal primary haemostasis in patients with chronic renal failure. Nephrol Dial Transplant: 1989; 4 11 971 974
58. Gromotowicz A., Szemraj J., Stankiewicz A., et al. Study of the mechanisms of aldosterone prothrombotic effect in rats. J Renin Angiotensin Aldosterone Syst: 2011; 12 4 430 439
59. Ducros E., Berthaut A., Mirshahi S. S., et al. Aldosterone modifies hemostasis via upregulation of the protein-C receptor in human vascular endothelium. Biochem Biophys Res Commun: 2008; 373 2 192 196
60. Ma J., Albornoz F., Yu C., Byrne D. W., Vaughan D. E., Brown N. J. Differing effects of mineralocorticoid receptor-dependent and -independent potassium-sparing diuretics on fibrinolytic balance. Hypertension: 2005; 46 2 313 320
61. Milliez P., Girerd X., Plouin P. F., Blacher J., Safar M. E., Mourad J. J. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol: 2005; 45 8 1243 1248
62. Verhamme K., Mosis G., Dieleman J., Stricker B., Sturkenboom M. Spironolactone and risk of upper gastrointestinal events: population based case-control study. BMJ: 2006; 333 7563 330
63. Erem C., Kocak M., Nuhoglu I., Ylmaz M., Ucuncu O. Blood coagulation, fibrinolysis and lipid profile in patients with prolactinoma. Clin Endocrinol (Oxf): 2010; 73 4 502 507
64. Wallaschofski H., Kobsar A., Koksch M., et al. Prolactin receptor signaling during platelet activation. Horm Metab Res: 2003; 35 4 228 235
65. Reuwer A. Q., Nieuwland R., Fernandez I., et al. Prolactin does not affect human platelet aggregation or secretion. Thromb Haemost: 2009; 101 6 1119 1127
66. van Zaane B., Squizzato A., Reuwer A. Q., et al. Prolactin and venous thrombosis: indications for a novel risk factor? Arterioscler Thromb Vasc Biol: 2011; 31 3 672 677
67. Stuijver D. J., Debeij J., van Zaane B., et al. Levels of prolactin in relation to coagulation factors and risk of venous thrombosis. Results of a large population-based case-control study (MEGA-study). Thromb Haemost: 2012; 108 3 499 507
68. Landin-Wilhelmsen K., Tengborn L., Wilhelmsen L., Bengtsson B. A. Elevated fibrinogen levels decrease following treatment of acromegaly. Clin Endocrinol (Oxf): 1997; 46 1 69 74
69. Erem C., Nuhoglu I., Kocak M., et al. Blood coagulation and fibrinolysis in patients with acromegaly: increased plasminogen activator inhibitor-1 (PAI-1), decreased tissue factor pathway inhibitor (TFPI), and an inverse correlation between growth hormone and TFPI. Endocrine: 2008; 33 3 270 276
70. Delaroudis S. P., Efstathiadou Z. A., Koukoulis G. N., et al. Amelioration of cardiovascular risk factors with partial biochemical control of acromegaly. Clin Endocrinol (Oxf): 2008; 69 2 279 284
71. Palmeiro C. R., Anand R., Dardi I. K., Balasubramaniyam N., Schwarcz M. D., Weiss I. A. Growth hormone and the cardiovascular system. Cardiol Rev: 2012; 20 4 197 207
72. Elhadd T. A., Abdu T. A., Oxtoby J., et al. Biochemical and biophysical markers of endothelial dysfunction in adults with hypopituitarism and severe GH deficiency. J Clin Endocrinol Metab: 2001; 86 9 4223 4232
73. Gómez J. M., Sahún M., Vila R., et al. Elevation of E-selectin concentrations may correlate with potential endothelial dysfunction in individuals with hypopituitarism during therapy with growth hormone. Curr Neurovasc Res: 2007; 4 1 55 62
74. Kvasnicka J., Marek J., Kvasnicka T., et al. Increase of adhesion molecules, fibrinogen, type-1 plasminogen activator inhibitor and orosomucoid in growth hormone (GH) deficient adults and their modulation by recombinant human GH replacement. Clin Endocrinol (Oxf): 2000; 52 5 543 548
75. Sartorio A., Cattaneo M., Bucciarelli P., et al. Alterations of haemostatic and fibrinolytic markers in adult patients with growth hormone deficiency and with acromegaly. Exp Clin Endocrinol Diabetes: 2000; 108 7 486 492
76. Devin J. K., Blevins L. S. Jr, Verity D. K., et al. Markedly impaired fibrinolytic balance contributes to cardiovascular risk in adults with growth hormone deficiency. J Clin Endocrinol Metab: 2007; 92 9 3633 3639